2025 Q4 -tulosraportti
67 päivää sitten
‧44 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 819 | - | - | ||
| 71 681 | - | - | ||
| 48 701 | - | - | ||
| 23 264 | - | - | ||
| 250 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 5.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 22.1.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·11 t sittenATH at approx. 16500 SEK for the current share size (32 SEK per share size back then) corresponded to a market capitalization of 2.44 billion SEK at the IPO back in 2016. Today, the market capitalization is 165 million SEK. With the current number of shares, the price must rise to approx. 4.5 SEK to return to the all-time high measured by total market capitalization.
·9 t sittenNot an unusual valuation for a Phase 3 company with good prospects?
·1 päivä sitten · MuokattuIt will be exciting to see if we ever beat previous ath here, then it would have made money for us who are now getting in under a krona... I myself have a GAV of 0.2, have a continued nice Saturday:-)
·14 t sittenDo you know what's even more exciting than money? Following the fight against cancer and revolutionary methods that can get rid of the damn thing.·14 t sittenof course, that is one of the reasons why I participate in, e.g., emissions in such companies...
·1 päivä sittenI have this stock, potential? And could someone share links about this stock?
·1 päivä sittenShort answer: Yes, there is enormous potential and upside – but with that potential also comes risk. The company's main project has presented outstanding data in a Phase 2 study, which has received significant attention. They are now preparing for a Phase 3 study, which will be very costly, and this is where the biggest risk lies. New share issues are common in biotech when capital needs to be raised, and that is the primary reason for the low market capitalization right now. An alternative is partnership agreements with larger pharmaceutical companies, which can secure funding for the Phase 3 study. This is also something many investors speculate about and an important explanation for the recent share price increase. The hope is that the recently published news signals increased interest from larger pharmaceutical companies to enter into partnerships.- ·1 päivä sitten · MuokattuNow corrected for calculation error: As a reference point, I have calculated what the average price is for 1 share if one started by buying 1 unit (2 shares) in connection with the new issue around February 2024 when a positive result from the phase 2 study was already known. I.e., 1000 shares at 1.07 SEK + 1000 shares at 0.55 SEK (TO9), which today would be 2 shares at a unit price of 810 SEK. If one with this position has since participated pro-rata in all new issues, then today one would have a total position of 748 shares with an average cost basis of 3.8 SEK per share. There is thus a good way up before the average invested value over the last 2 years is reached. Does anyone arrive at the same conclusion? Has anyone looked further back?
- ·2 päivää sittenThis was positive * 100 % of patients show immune response (6/6) * increased number of neoantigen responses in several patients * combination (IRE + CD40) shows "systemic effect"-signal * PDAC is an extremely difficult area → even small signals can be interpreted positively 👉 This gives a "bull case": the mechanism works in humans1 päivä sitten1 päivä sittenAI dravel.
·14 t sitten · MuokattuIf a partnership is entered into in the next few days, then I absolutely believe that. Or if it suddenly emerges that they will participate in ASCO Annual as well. I'm actually a bit glad this one hasn't had the same explosion as Circio. I feel it's a bit «healthier», if that makes sense.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
67 päivää sitten
‧44 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11 t sittenATH at approx. 16500 SEK for the current share size (32 SEK per share size back then) corresponded to a market capitalization of 2.44 billion SEK at the IPO back in 2016. Today, the market capitalization is 165 million SEK. With the current number of shares, the price must rise to approx. 4.5 SEK to return to the all-time high measured by total market capitalization.·9 t sittenNot an unusual valuation for a Phase 3 company with good prospects?
- ·1 päivä sitten · MuokattuIt will be exciting to see if we ever beat previous ath here, then it would have made money for us who are now getting in under a krona... I myself have a GAV of 0.2, have a continued nice Saturday:-)·14 t sittenDo you know what's even more exciting than money? Following the fight against cancer and revolutionary methods that can get rid of the damn thing.·14 t sittenof course, that is one of the reasons why I participate in, e.g., emissions in such companies...
- ·1 päivä sittenI have this stock, potential? And could someone share links about this stock?·1 päivä sittenShort answer: Yes, there is enormous potential and upside – but with that potential also comes risk. The company's main project has presented outstanding data in a Phase 2 study, which has received significant attention. They are now preparing for a Phase 3 study, which will be very costly, and this is where the biggest risk lies. New share issues are common in biotech when capital needs to be raised, and that is the primary reason for the low market capitalization right now. An alternative is partnership agreements with larger pharmaceutical companies, which can secure funding for the Phase 3 study. This is also something many investors speculate about and an important explanation for the recent share price increase. The hope is that the recently published news signals increased interest from larger pharmaceutical companies to enter into partnerships.
- ·1 päivä sitten · MuokattuNow corrected for calculation error: As a reference point, I have calculated what the average price is for 1 share if one started by buying 1 unit (2 shares) in connection with the new issue around February 2024 when a positive result from the phase 2 study was already known. I.e., 1000 shares at 1.07 SEK + 1000 shares at 0.55 SEK (TO9), which today would be 2 shares at a unit price of 810 SEK. If one with this position has since participated pro-rata in all new issues, then today one would have a total position of 748 shares with an average cost basis of 3.8 SEK per share. There is thus a good way up before the average invested value over the last 2 years is reached. Does anyone arrive at the same conclusion? Has anyone looked further back?
- ·2 päivää sittenThis was positive * 100 % of patients show immune response (6/6) * increased number of neoantigen responses in several patients * combination (IRE + CD40) shows "systemic effect"-signal * PDAC is an extremely difficult area → even small signals can be interpreted positively 👉 This gives a "bull case": the mechanism works in humans1 päivä sitten1 päivä sittenAI dravel.·14 t sitten · MuokattuIf a partnership is entered into in the next few days, then I absolutely believe that. Or if it suddenly emerges that they will participate in ASCO Annual as well. I'm actually a bit glad this one hasn't had the same explosion as Circio. I feel it's a bit «healthier», if that makes sense.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 819 | - | - | ||
| 71 681 | - | - | ||
| 48 701 | - | - | ||
| 23 264 | - | - | ||
| 250 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 5.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 22.1.2025 |
2025 Q4 -tulosraportti
67 päivää sitten
‧44 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 5.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 22.1.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11 t sittenATH at approx. 16500 SEK for the current share size (32 SEK per share size back then) corresponded to a market capitalization of 2.44 billion SEK at the IPO back in 2016. Today, the market capitalization is 165 million SEK. With the current number of shares, the price must rise to approx. 4.5 SEK to return to the all-time high measured by total market capitalization.·9 t sittenNot an unusual valuation for a Phase 3 company with good prospects?
- ·1 päivä sitten · MuokattuIt will be exciting to see if we ever beat previous ath here, then it would have made money for us who are now getting in under a krona... I myself have a GAV of 0.2, have a continued nice Saturday:-)·14 t sittenDo you know what's even more exciting than money? Following the fight against cancer and revolutionary methods that can get rid of the damn thing.·14 t sittenof course, that is one of the reasons why I participate in, e.g., emissions in such companies...
- ·1 päivä sittenI have this stock, potential? And could someone share links about this stock?·1 päivä sittenShort answer: Yes, there is enormous potential and upside – but with that potential also comes risk. The company's main project has presented outstanding data in a Phase 2 study, which has received significant attention. They are now preparing for a Phase 3 study, which will be very costly, and this is where the biggest risk lies. New share issues are common in biotech when capital needs to be raised, and that is the primary reason for the low market capitalization right now. An alternative is partnership agreements with larger pharmaceutical companies, which can secure funding for the Phase 3 study. This is also something many investors speculate about and an important explanation for the recent share price increase. The hope is that the recently published news signals increased interest from larger pharmaceutical companies to enter into partnerships.
- ·1 päivä sitten · MuokattuNow corrected for calculation error: As a reference point, I have calculated what the average price is for 1 share if one started by buying 1 unit (2 shares) in connection with the new issue around February 2024 when a positive result from the phase 2 study was already known. I.e., 1000 shares at 1.07 SEK + 1000 shares at 0.55 SEK (TO9), which today would be 2 shares at a unit price of 810 SEK. If one with this position has since participated pro-rata in all new issues, then today one would have a total position of 748 shares with an average cost basis of 3.8 SEK per share. There is thus a good way up before the average invested value over the last 2 years is reached. Does anyone arrive at the same conclusion? Has anyone looked further back?
- ·2 päivää sittenThis was positive * 100 % of patients show immune response (6/6) * increased number of neoantigen responses in several patients * combination (IRE + CD40) shows "systemic effect"-signal * PDAC is an extremely difficult area → even small signals can be interpreted positively 👉 This gives a "bull case": the mechanism works in humans1 päivä sitten1 päivä sittenAI dravel.·14 t sitten · MuokattuIf a partnership is entered into in the next few days, then I absolutely believe that. Or if it suddenly emerges that they will participate in ASCO Annual as well. I'm actually a bit glad this one hasn't had the same explosion as Circio. I feel it's a bit «healthier», if that makes sense.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 819 | - | - | ||
| 71 681 | - | - | ||
| 48 701 | - | - | ||
| 23 264 | - | - | ||
| 250 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt